EGM Statement

Fulcrum Pharma PLC
10 June 2002


For Immediate Release:                                       Monday 10 June 2002


                               FULCRUM PHARMA PLC


              Statement from Extraordinary General Meeting ('EGM')


At the Extraordinary General Meeting held today, Monday, 10 June 2002, for
Fulcrum Pharma, the independent drug development company, all resolutions were
duly passed.

At the EGM the statement set out below was read:

'Following the announcement of our interim results on 16 May 2002 I am delighted
to be able to report that Fulcrum continues to trade in line with expectations.
Our successful fundraising has enabled us to progress rapidly with our
international development activities and we will announce the opening of a US
office before the end of the summer. This is the next step in our expansion
programme, which will include growth in Europe as well as the conversion of our
already successful Japanese operation into a full subsidiary.

'As announced this morning we have initiated a development agreement with The
Medicines for Malaria Venture, a public-private partnership, for the discovery
and development of new anti-malarial drugs - we look forward to announcing
further exciting partnerships during the course of this year.

'We view the outlook for the business going forward with confidence.'


                                    - ENDS -


For further information, please contact :
Fulcrum Pharma PLC
Jon Court, Chief Executive                                0870 7107152

Buchanan Communications
Nicola How / Louise Bolton                                0207 466 5000



Notes to Editors:

Fulcrum Pharma plc is an independent, strategic, drug development services
company that aims to be the pharmaceutical industry's first choice for optimal
management of drug development.

Fulcrum offers a unique strategic drug development service to the pharmaceutical
and biotechnology industries. The company provides customized development
programmes that lead to early Proof of Concept, efficient registration and ideal
positioning for rapid availability to patients. Fulcrum's service is
professional and cost-effective.

Fulcrum's experienced senior managers personally oversee drug development
projects via an advanced management process, combining exceptional project
leadership and problem solving skills with an external team of specifically
selected suppliers and independent experts to meet the needs of our clients.

Fulcrum Pharma is listed on the Alternative Investment Market of the London
Stock Exchange.


                      This information is provided by RNS
            The company news service from the London Stock Exchange